Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

作者: Isa E.L.M. Kuppens , Jos H. Beijnen , Jan H.M. Schellens

DOI: 10.3816/CCC.2004.N.017

关键词: ExatecanTopotecanApical membraneIrinotecanMedicineLurtotecanPharmacologyInternal medicineRubitecanOncologyCancerOral administration

摘要: This article reviews the current status of topoisomerase I (top I) inhibitors in treatment gastrointestinal (GI) malignancies. We focus on oral drug administration, mode administration that is generally preferred by patients with cancer. However, great majority studies have been performed intravenous (I.V.) administration. The most extensively investigated GI malignancy phase I/II colorectal cancer (CRC), for which I.V. irinotecan currently approved United States and Europe. discuss activity efficacy as a single agent CRC combination regimens. Also, results obtained monotherapy other malignancies such esophageal, gastric, pancreatic are discussed. Few its clinical has not yet fully determined. Several top discussed, including topotecan, 9-aminocamptothecin, rubitecan, exatecan, lurtotecan. None these agents, given orally or intravenously, shown similar to irinotecan. several agents show promising malignancies, eg, rubitecan exatecan A complicating factor often encountered low variable bioavailability. can partly be explained high affinity efflux pumps BCRP (ABCG2) P-glycoprotein, highly expressed epithelial apical membrane tract. novel approach improve bioavailability temporary blockade transporter described.

参考文章(152)
Jimmy J Hwang, John L Marshall, Steven G Eisenberg, Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology. ,vol. 17, pp. 37- 43 ,(2003)
John S. Macdonald, Joth L. Jacobson, Steven J Ketchel, Geoffrey Weiss, Sarah Taylor, Glenn Mills, J. Phillip Kuebler, Saul Rivkin, Marcel Conrad, A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339). Investigational New Drugs. ,vol. 18, pp. 199- 202 ,(2000) , 10.1023/A:1006390216220
Jordan D. Berlin, Targeting vascular endothelial growth factor in colorectal cancer. Oncology. ,vol. 16, pp. 13- 15 ,(2002)
Jacqueline K. Benedetti, Howard A. Burris III, Stanley P. Balcerzak, John S. Macdonald, Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group study. Investigational New Drugs. ,vol. 15, pp. 261- 264 ,(1997) , 10.1023/A:1005899720463
H C Pitot, D B Wender, M J O'Connell, G Schroeder, R M Goldberg, J Rubin, J A Mailliard, J A Knost, C Ghosh, R J Kirschling, R Levitt, H E Windschitl, Phase II Trial of Irinotecan in Patients With Metastatic Colorectal Carcinoma Journal of Clinical Oncology. ,vol. 15, pp. 2910- 2919 ,(1997) , 10.1200/JCO.1997.15.8.2910
A Wakui, T Taguchi, Y Sakata, M Yoshino, Y Shimada, K Futatsuki, I Nakao, N Ogawa, M Kambe, [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 1033- 1038 ,(1994)
Richard Pazdur, Diana C. Medgyesy, Rodger J. Winn, S.R. Dakhil, Dennis F. Moore, Jr., Anthony Scalzo, Paulo M. Hoff, Susan G. Arbuck, James L. Abbruzzese, Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma Investigational New Drugs. ,vol. 16, pp. 341- 346 ,(1998) , 10.1023/A:1006248700232
P C Enzinger, D H Ilson, D P Kelsen, Chemotherapy in esophageal cancer Seminars in Oncology. ,vol. 26, pp. 12- 20 ,(1999)
A. Sparreboom, K. Nooter, C. J. A. Punt, M. G. Porro, W. J. Loos, M. J. A. De Jonge, J. Verweij, Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clinical Cancer Research. ,vol. 4, pp. 1915- 1919 ,(1998)